Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

atient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Andrea tenBroek

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA ... which spotlights treating depression. Depression affects millions of Americans every single year. To ... inform and enlighten viewers with the latest segment produced with the assistance of ...
(Date:8/3/2015)... , ... August 04, 2015 , ... ... Armethia Holt as a 2015-2016 inductee into the NAPW VIP Woman of ... healthcare. With more than 700,000 members and over 200 operating Local Chapters, NAPW ...
(Date:8/3/2015)... ... ... offers the most affordable web design and SEO services for start up companies. Every ... dollar. Every company that is starting out needs to be online in this technology ... a start up need to be online, they need to physically be present and visible ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... In a follow-up study, researchers at Moffitt Cancer Center and ... cancer might experience prolonged fatigue years after their therapy. The ... of CANCER , is a follow-up to a study ... researchers published in CANCER in 2007. "Fatigue ...
... , MONDAY, Dec. 5 (HealthDay News) --,Hospitalized patients ... most common cause of infectious diarrhea in hospitals -- will ... new study indicates. Experts say prevention is key to ... C. difficile . For the study, published Dec. 5 ...
... News) -- Teenagers with autism who also have epilepsy ... The combination means that certain behaviors common among ... front of their faces -- could increase their risk ... to 14 percent of children with epilepsy, the rate ...
... By Alan Mozes HealthDay Reporter , SUNDAY, Dec. ... to face an increased risk for seizures while watching 3-D ... did reveal that about one in five of these children ... including nausea, headaches and dizziness. "Normal people have a ...
... University of New Hampshire Crimes against Children Research Center suggest ... found the percentage of youth who send nude pictures of ... The other found that when teen sexting images do come ... like sex offenders. The studies were carried out by ...
... Barcelona, 1st December, 2011.- A study by researchers Ral ... in Biomedicine (IRB Barcelona) and Pilar Navarro at the ... a new reprogramming mechanism for the expression of genes ... cell. In the study, published in this week,s edition ...
Cached Medicine News:Health News:Follow-up study finds prolonged fatigue for those who had chemotherapy for breast cancer 2Health News:Common Hospital Infection Lengthens Patient Stays 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 3Health News:Concerns about teen sexting overblown, according to new UNH research 2Health News:Discovery of a new reprogramming mechanism for tumor cells 2
Designed to safely and easily removing a cataract nucleus, round serrated handle, dull finish....
Round handle dull finish. For right handed surgeon....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: